Numbers

Figures converted from HKD at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Numbers

Blue Moon trades at $0.40 — down 79% from its December 2020 IPO — because the company deliberately sacrificed profitability to fund a channel transformation. Gross margins hold at 60%, confirming premium brand economics, but selling expenses more than doubled from 29% to 59% of revenue between FY2020 and FY2024, converting $225M of operating income into a $129M operating loss. The balance sheet carries zero debt and $478M net cash, yet that pile has shrunk by two-thirds since listing. Q4 2025 returned to quarterly profit ($7M net income), and consensus expects full-year profitability by FY2026. The single metric that will rerate this stock is the selling expense ratio — every 5-percentage-point reduction on current revenue adds roughly $54M to operating income.

At a Glance

Share Price ($)

0.40

Market Cap ($ B)

2.35

EV / Sales

1.74

Dividend Yield

5.8%

Net Cash ($ B)

0.48

Quality Score and Fair Value estimates are not available for this company in the data pipeline. All figures in USD unless otherwise stated.

Revenue & Earnings Power

A $1.1B-revenue consumer staples business — China's leading liquid laundry detergent brand by market share for 16 consecutive years — that generates 60% gross margins but currently loses money at the operating level due to outsized channel investment spending.

Revenue grew 20% since IPO — modest but steady for consumer staples. Operating income collapsed from $225M (25% margin) to negative $46M. The top line is fine; the cost structure broke.

The Selling Expense Problem

This is the chart that explains the stock price. Blue Moon more than doubled its selling and distribution expenses as a percentage of revenue — from 29% to 59% — to push concentrated detergent adoption through online channels. FY2025 marks the first year of pullback.

Selling expenses at 53% of revenue remain nearly double the FY2020 level of 29%. The FY2025 drop from 59% to 53% saved roughly $64M, driving the net loss reduction from $96M to $42M. G&A has been well-managed throughout at 11-15%.

Margin Trends

Gross margins have held between 58-65% throughout — the product economics are structurally sound. The entire margin collapse occurs below the gross line, driven solely by selling expenses. In FY2023, net margin (4.4%) exceeded operating margin (1.8%) because $35M of finance income from the cash pile bridged the gap.

Since FY2022, dividends have exceeded earnings. In FY2024 and FY2025, the company paid dividends while reporting net losses — funded entirely from the IPO cash pile. Total dividends since listing: roughly $450M, nearly equal to the current net cash of $478M. Management also authorized a 10% share buyback plan (586M shares) in March 2026, signaling confidence in the turnaround but further depleting cash reserves. FY2025 capex was a modest $24M (2.2% of revenue), confirming this is not a capital-intensive business.

Cash Generation

No formal cash flow statement is available in the data pipeline. However, the picture is clear from the balance sheet: levered free cash flow was approximately negative $81M in FY2025 per trailing data — worse than the reported net loss of $42M. The gap is explained by working capital deterioration: trade receivables expanded from $156M to $213M during FY2025. Cash conversion is currently poor; reported earnings overstate the company's actual cash generation.

Balance Sheet — The Cash Fortress Is Shrinking

Debt / Equity

0.0

Current Ratio

4.2

Book Value/Share ($)

0.16

FY2025 Capex ($ M)

Zero debt. Current ratio of 4.2x. But net cash has declined at roughly $180M per year since listing. At the FY2025 burn rate, the cash cushion has about 2-3 years of runway before it constrains dividends. The balance sheet is fortress-like on paper, but the walls are shrinking every quarter.

Revenue Mix

Fabric care (liquid laundry detergent) accounts for 88% of revenue. Online channels represent 59% of sales. This concentration means the fate of the entire business rides on the concentrated detergent adoption cycle in China.

No Results

Personal hygiene grew 12.8% in FY2025, driven by the Jingxiang foaming body wash launch — the only segment showing momentum.

Valuation — Since IPO

Blue Moon listed in December 2020, so the full public-market record spans five years — not 20. The IPO valuation of 11x EV/Sales and 7.5x P/B reflected pandemic-era enthusiasm for Chinese consumer brands. Both multiples have compressed dramatically as losses mounted and the cash pile shrank.

EV/Sales (Current)

1.74

P/B (Current)

2.4

Fwd P/E (FY2026e)

45.5

Consensus Target ($)

0.32

EV/Sales has compressed from 11.0x at IPO to 1.7x today — still above the 2023 trough of 0.7x when the stock bottomed. At 45x forward P/E on consensus FY2026 earnings (approximately $51M net income), the stock is expensive for consumer staples — the market is pricing a turnaround that has not yet been fully proven. The analyst consensus target of $0.32 sits 20% below the current price.

Stock Price — The 79% Decline

IPO price: $1.92 (December 2020). Current: $0.40. The stock bottomed at $0.22 in mid-2024 before recovering above $0.38. The 52-week range is $0.32 to $0.56. The all-time high of $2.46 was reached in early 2021.

Peer Comparison

No Results

Blue Moon (marked with *) has the highest gross margin in the peer group at 60%, yet is the only company running at a net loss. That paradox — best gross economics, worst bottom line — is entirely explained by the 53% selling expense ratio, roughly double the industry norm. P&G commands a 4.7x EV/Sales premium because it delivers consistent 18% net margins; Blue Moon's 1.7x reflects a market that does not yet trust the turnaround. The closest comparable, Shanghai Jahwa, trades at a higher EV/Sales despite lower gross margins because it is profitable.

Fair Value & Scenario

Bear Case ($)

0.23

Base Case ($)

0.40

Bull Case ($)

0.58

Bear ($0.23): Selling expense stays above 50%, losses persist through FY2027, cash drops below $257M, dividend is cut. The stock re-tests its 2024 lows. This requires management to abandon the discipline shown in H2 2025.

Base ($0.40): FY2026 turns profitable per consensus (approximately $51M NI), selling expense normalizes to 45-48%, dividend maintained. Forward P/E of 35-40x on modest recovery earnings, plus $0.08/share cash cushion. This is roughly where the stock trades today — meaning the turnaround is priced in.

Bull ($0.58): Selling expense normalizes to 38-40% by FY2027, operating margins recover to 8-12%, net income reaches $77M or above. P/E compresses to 25-30x as the turnaround is proven. Revenue grows mid-single digits. This requires two more years of consistent execution.

The numbers confirm Blue Moon is a structurally sound consumer staples business — 60% gross margins, zero debt, dominant brand positioning in China's liquid detergent category — that temporarily broke its own economics by overspending on channel transformation. The popular "buy the turnaround" narrative is partially contradicted by the valuation: at $0.40, the stock already trades above the analyst consensus of $0.32 and prices in FY2026 profitability at a 45x forward P/E, which is expensive even for premium consumer franchises. The metric to watch in the next two quarters is the selling expense ratio: if H1 2026 comes in below 48%, the path to structural profitability is confirmed and the stock has room to re-rate toward $0.51 to $0.64. If it stays above 50%, the thesis loses credibility and the cash drain re-accelerates toward levels that threaten the dividend.